João Carlos de Campos Guerra

João Carlos de Campos Guerra

Auto-generated profile, based on publicly available information

João Carlos de Campos Guerra

Departamento de Patologia Clínica, Medicina Diagnóstica, Hospital Israelita Albert Einstein, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PDPriscilla Bento Matos Derogis
Priscilla Bento Matos Derogis
LSLivia Rentas Sanches
Livia Rentas Sanches
VAValdir Fernandes de Aranda
Valdir Fernandes de Aranda
MCMarjorie Paris Colombini
Marjorie Paris Colombini
CMCristóvão Luis Pitangueira Mangueira
Cristóvão Luis Pitangueira Mangueira
JGJoão Carlos de Campos Guerra
João Carlos de Campos Guerra
Rivaroxaban is an oral direct factor Xa inhibitor, therapeutically indicated in the treatment of thromboembolic diseases. As other new oral anticoagulants, routine monitoring of rivaroxaban is not necessary, but important in some clinical circumstances. In our study a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was validated to measure rivaroxaban plasmatic concentration. Our method used a simple sample preparation, protein precipitation, and a fast chromatographic run. It was developed a precise and accurate method, with a linear range from 2 to 500 ng/mL, and a lower limit of quantification of 4 pg on column. The new method was compared to a reference method (anti-factor Xa activity) and both presented a good correlation (r = 0.98, p < 0.001). In addition, we validated hemolytic, icteric or lipemic plasma samples for rivaroxaban measurement by HPLC-MS/MS without interferences. The chromogenic and HPLC-MS/MS methods were highly correlated and should be used as clinical tools for drug monitoring. The method was applied successfully in a group of 49 real-life patients, which allowed an accurate determination of rivaroxaban in peak and trough levels.

29 May 2020 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
GMGustavo Faissol Janot de Matos
Gustavo Faissol Janot de Matos
BBBruno de Arruda Bravim
Bruno de Arruda Bravim
RCRicardo Luiz Cordioli
Ricardo Luiz Cordioli
AGAlejandra del Pilar Gallardo Garrido
Alejandra del Pilar Gallardo Garrido
LFLeonardo José Rolim Ferraz
Leonardo José Rolim Ferraz
In December 2019, a series of patients with severe pneumonia were identified in Wuhan, Hubei province, China, who progressed to severe acute respiratory syndrome and acute respiratory distress syndrome. Subsequently, COVID-19 was attributed to a new betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Approximately 20% of patients diagnosed as COVID-19 develop severe forms of the disease, including acute hypoxemic respiratory failure, severe acute respiratory syndrome, acute respiratory distress syndrome and acute renal failure and require intensive care. There is no randomized controlled clinical trial addressing potential therapies for patients with confirmed COVID-19 infection at the time of publishing these treatment recommendations. Therefore, these recommendations are based predominantly on the opinion of experts (level C of recommendation).

19 January 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
FMFelipe Maia
Felipe Maia
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
Alexandre MarraAlexandre Marra
Alexandre Marra
JGJoão Carlos Campos Guerra
João Carlos Campos Guerra
RRRoseny dos Reis Rodrigues
Roseny dos Reis Rodrigues
ACAlexandre Biasi Cavalcanti
Alexandre Biasi Cavalcanti
Dengue virus infection (DVI) is a prevalent and potentially fatal viral disease associated with coagulopathy. So far, the coagulation profile of DVI patients with thrombocytopenia has not been assessed through a viscoelastic test such as rotational thromboelastometry. We aimed to describe the prevalence and characteristics of coagulation abnormalities in dengue fever outpatients with thrombocytopenia, addressed by both rotational thromboelastometry and conventional coagulation tests. This was a cross-sectional study conducted between April 6th and May 5th 2015 in São Paulo, Brazil during a dengue outbreak. Thromboelastometry (ROTEM®) and the conventional coagulation tests prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), thrombin time (TT), platelet count and fibrinogen levels were performed in 53 patients with DVI and thrombocytopenia. Despite a median interquartile range (IQR) platelet count of 77 (63–88) x 109/L in DVI patients, conventional coagulation tests and plasma fibrinogen levels were within the normal range. Subjects demonstrated hypocoagulability in 71.7% (38/53) in INTEM and 54.7% (29/53) in EXTEM DVI patients. FIBTEM analyses detected only 5.7% (3/53) with hypocoagulability among this population. The median (IQR) clotting time (CT), clot formation time (CFT) and maximum clot firmness (MCF) on INTEM were, respectively, 177 (160–207) sec, 144 (108–178) sec and 48 (42–52) mm. On EXTEM, median (IQR) CT, CFT and MCF were, respectively, 69 (65–78) sec, 148 (126–198) sec and 49 (44–55) mm. Median (IQR) MCF on FIBTEM was 15 (13–18) mm. Thromboelastometry impairment is highly prevalent in DVI patients with thrombocytopenia, particularly in INTEM and EXTEM analyses, while standard coagulation tests are normal in this setting. Clinical implications remain to be established.

13 August 2019 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
CNClaudia Mac Donald Bley Nascimento
Claudia Mac Donald Bley Nascimento
AMAndréa Maria Novaes Machado
Andréa Maria Novaes Machado
JGJoão Carlos de Campos Guerra
João Carlos de Campos Guerra
EZEduardo Zlotnik
Eduardo Zlotnik
DCDirceu Hamilton Cordeiro Campêlo
Dirceu Hamilton Cordeiro Campêlo
NHNelson Hamerschlak
Nelson Hamerschlak
To standardize the investigation and clinical management of women with laboratory and/or clinical abnormalities suggestive of thrombophilia, in order to optimize antithrombotic approach and indication of laboratory tests. A discussion was carried out among 107 physicians (gynecologists/obstetricians, hematologists and vascular surgeons) present at a forum held at the Hospital Israelita Albert Einstein, in São Paulo (SP), Brazil. As a minimum criterion, 80% agreement was established in the voting to each recommendation of conduct in the final document. The cases in which there was agreement below 80% were discussed again, reaching a consensual agreement of conduct for the document writing. The standardization of an institutional consensus of suggestions of clinical approach contributes to a better management of the group to be evaluated and minimizes risks of intercurrent events. This was the first national consensus on the investigation of thrombophilia in women.

31 July 2020 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
GMGustavo Faissol Janot de Matos
Gustavo Faissol Janot de Matos
BBBruno de Arruda Bravim
Bruno de Arruda Bravim
RCRicardo Luiz Cordioli
Ricardo Luiz Cordioli
AGAlejandra del Pilar Gallardo Garrido
Alejandra del Pilar Gallardo Garrido
LFLeonardo José Rolim Ferraz
Leonardo José Rolim Ferraz
Dear Editor, In this issue of einstein journal (São Paulo), Corrêa et al., reported intensive support recommendations for critically-ill patients with suspected or confirmed infection by the new coronavirus (COVID-19).() Based on preliminary demonstration of efficacy of chloroquine, the authors suggested the use of hydroxychloroquine in monotherapy or combined with a macrolide (azithromycin or clarithromycin), to treat severe patients with COVID-19, admitted to the intensive care unit (ICU), to inhibit in vitro replication of severe acute respiratory syndrome coronavirus 2 [...] Dear Editor, In this issue of einstein journal (São Paulo), Corrêa et al., reported intensive support recommendations for critically-ill patients with suspected or confirmed infection by the new coronavirus (COVID-19).() Based on preliminary demonstration of efficacy of chloroquine, the authors suggested the use of hydroxychloroquine in monotherapy or combined with a macrolide (azithromycin or clarithromycin), to treat severe patients with COVID-19, admitted to the intensive care unit (ICU), to inhibit in vitro replication of severe acute respiratory syndrome coronavirus 2

1 January 2019 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
VAV.F. de Aranda
V.F. de Aranda
PDP.B.M. Derogis
P.B.M. Derogis
LSL.R. Sanches
L.R. Sanches
CMC.L.P. Mangueira
C.L.P. Mangueira
MKM. Katz
M. Katz
JGJ.C. de Campos Guerra
J.C. de Campos Guerra
The aim of the study was to evaluate the diagnostic accuracy of thromboelastometry for assessing rivaroxaban concentrations. The accuracy of thromboelastometry was compared with the high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method, which is the gold standard for drug plasma monitoring (the reference standard). Forty-six clinically stable patients were treated with 10, 15, or 20 mg of rivaroxaban once daily (OD group) or 15 mg twice a day (BID group) (no particular indication for treatment). Patient samples were collected 2 h after the use of the medication (peak) and 2 h before the next dose (trough). The rivaroxaban plasma concentrations were determined via HPLC-MS/MS, and thromboelastometry was performed using a ROTEM® delta analyzer. There were significant prolongations in clotting time (CT) for the 10, 15, and 20 mg of rivaroxaban treatments in the OD groups. In the 15 mg BID group, the responses at the peak and trough times were similar. At the peak times, there was a positive correlation between the plasma concentration of rivaroxaban and CT (Spearman correlation rho=0.788, P<0.001) and clot formation time (rho=0.784, P<0.001), and a negative correlation for alpha angle (rho=−0.771, P<0.001), amplitude after 5 min (rho=−0.763, P<0.001), and amplitude after 10 min (rho=−0.680, P<0.001). The CT presented higher specificity and sensitivity using the cut-off determined by the receiver characteristics curve. ROTEM has potential as screening tool to measure possible bleeding risk associated with rivaroxaban plasma levels.